Sugi Predict

Sugi Predict / Compounds / SCHEMBL18970284

SCHEMBL18970284

SCHEMBL18970284

C[C@H](CC(=O)Cc1ccc(-c2ccccc2)cc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ABCC4 O15439 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ PTGS1 P23219 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.51
▸ HPGD P15428 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ MME P08473 8/20 0.50
▸ ACE P12821 8/20 0.50
▸ PTGS2 P35354 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18970304 1.00 ABCC4 (0.55) ABCC4LMNAGAATSHRPTGS1
SCHEMBL21633582 0.90 TSHR (0.50) TSHRMAPTKMT2AMEN1
SCHEMBL21633584 0.90 TSHR (0.50) TSHRMAPTKMT2AMEN1
SCHEMBL22295411 0.89 LMNA (0.53) ABCC4LMNAGAATSHRPTGS1
SCHEMBL21572800 0.87 LMNA (0.51) ABCC4LMNAGAATSHRPTGS1
SCHEMBL24555290 0.86 LMNA (0.50) ABCC4LMNAGAATSHRPTGS1
SCHEMBL31558355 0.86 LMNA (0.50) ABCC4LMNAGAATSHRPTGS1
SCHEMBL31558358 0.86 LMNA (0.50) ABCC4LMNAGAATSHRPTGS1
SCHEMBL20583510 0.84 ALDH1A1 (0.50) ABCC4LMNAGAATSHRPTGS1
SCHEMBL20583484 0.84 ALDH1A1 (0.50) ABCC4LMNAGAATSHRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111032682-B Engineered transaminase polypeptides for industrial biocatalysis 科德克希思公司 2024-04-12 — — CN claimed
EP-3424899-B1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2022-05-11 — — EP claimed
US-10479753-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD (CN) 2019-11-19 — — US claimed
EP-3424899-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2019-01-09 — — EP claimed
US-20180362439-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-12-20 — — US claimed
US-20250250550-A1 ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS CODEXIS INC (US) 2025-08-07 — — US disclosed
US-12297462-B2 Engineered transaminase polypeptides for industrial biocatalysis CODEXIS, INC. (US) 2025-05-13 — — US disclosed
CN-119798080-A Preparation method of (R) -5- ([ 1,1' -biphenyl ] -4-yl) -2-methyl-4-oxopentanoic acid calcium salt 杭州科巢生物科技有限公司 2025-04-11 — — CN disclosed
CN-111032682-B Engineered transaminase polypeptides for industrial biocatalysis 科德克希思公司 2024-04-12 — — CN disclosed
CN-108602785-B Novel processes and intermediates 诺华股份有限公司 2023-08-11 — — CN disclosed
US-20220282229-A1 ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2022-09-08 — — US disclosed
US-11434192-B2 Process and intermediates NOVARTIS AG (CH) 2022-09-06 — — US disclosed
US-20190308927-A1 PROCESS AND INTERMEDIATES NOVARTIS PHARMA AG (CH) 2019-10-10 — — US disclosed
US-10377697-B2 Process and intermediates NOVARTIS AG (CH) 2019-08-13 — — US disclosed
US-10377697-B2 Process and intermediates NOVARTIS AG (CH) 2019-08-13 — — US disclosed
EP-3424899-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2019-01-09 — — EP disclosed
WO-2018231462-A1 ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS CODEXIS, INC. (US) 2018-12-20 — — WO disclosed
US-20180362439-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-12-20 — — US disclosed
US-20180354889-A1 NEW PROCESS AND INTERMEDIATES NOVARTIS AG (CH) 2018-12-13 — — US disclosed
WO-2017098430-A1 NEW PROCESS AND INTERMEDIATES NOVARTIS AG (CH) 2017-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308927-A1 PROCESS AND INTERMEDIATES MME, ACE, DNPEP ABCC4 3483/4885LMNA 1901/4885GAA 71/4885
US-20180354889-A1 NEW PROCESS AND INTERMEDIATES MME, ACE, DNPEP ABCC4 3438/4885LMNA 2101/4885GAA 79/4885
US-10377697-B2 Process and intermediates MME, ACE, DNPEP ABCC4 3483/4885LMNA 1901/4885GAA 71/4885
US-20180362439-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF ACE, DPP4, SI ABCC4 3613/4885LMNA 2313/4885GAA 63/4885
US-10479753-B2 Sacubitril intermediate and preparation method thereof ACE, DPP4, SI ABCC4 3613/4885LMNA 2313/4885GAA 63/4885
US-11434192-B2 Process and intermediates MME, ACE, DNPEP ABCC4 3483/4885LMNA 1901/4885GAA 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback